Neuphoria Therapeutics Inc. Foreign Currency Transaction Gain (Loss), before Tax
Neuphoria Therapeutics Inc. (NEUP) reported Foreign Currency Transaction Gain (Loss), before Tax of -$603.31 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-09-18
- Neuphoria Therapeutics Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$843.07K.
- Neuphoria Therapeutics Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was $496.69K, a 40.59% increase year-over-year.
- Neuphoria Therapeutics Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$224.29K, a 143.70% decline year-over-year.
- Neuphoria Therapeutics Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$32.64K.
- Neuphoria Therapeutics Inc. foreign currency transaction gain (loss), before tax for fiscal 2026 was -$603.31K.
- Neuphoria Therapeutics Inc. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$242.35K, a 986.10% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. foreign currency transaction gain (loss), before tax for fiscal 2024 was $27.35K, a 95.09% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. foreign currency transaction gain (loss), before tax for fiscal 2023 was $556.78K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$843.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$346.38K derived: sum of 2 quarters · filed 2026-09-18 | -$570.67K derived: sum of 3 quarters · filed 2026-09-18 | -$603.31K 10-K · filed 2026-09-18 |
| 2026-03-31 | $496.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $272.40K derived: sum of 2 quarters · filed 2026-05-15 | $239.76K 10-Q · filed 2026-05-15 | -$636.13K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$224.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$256.93K 10-Q · filed 2026-02-17 | -$1.13M derived: sum of 3 quarters · filed 2026-09-18 | -$779.53K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$32.64K 10-Q · filed 2025-11-14 | -$908.53K derived: sum of 2 quarters · filed 2026-09-18 | -$555.24K derived: sum of 3 quarters · filed 2026-09-18 | -$41.95K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$875.89K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$522.60K derived: sum of 2 quarters · filed 2026-09-18 | -$9.30K derived: sum of 3 quarters · filed 2026-09-18 | -$242.35K 10-K · filed 2026-09-18 |
| 2025-03-31 | $353.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $866.58K derived: sum of 2 quarters · filed 2026-05-15 | $633.54K 10-Q · filed 2026-05-15 | $720.79K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $513.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $280.25K 10-Q · filed 2026-02-17 | $367.50K derived: sum of 3 quarters · filed 2026-02-17 | $576.52K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$233.04K 10-Q · filed 2025-11-14 | -$145.80K derived: sum of 2 quarters · filed 2025-11-14 | $63.23K derived: sum of 3 quarters · filed 2025-11-14 | -$138.38K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $87.25K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $296.28K derived: sum of 2 quarters · filed 2025-09-29 | $94.67K derived: sum of 3 quarters · filed 2025-09-29 | $27.35K 10-K · filed 2025-09-29 |
| 2024-03-31 | $209.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | $7.42K derived: sum of 2 quarters · filed 2025-05-20 | -$59.90K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$201.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$268.93K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$67.32K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $556.78K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |